title: Additional events in the RE-LY trial.
authors.affiliation: McMaster University, Hamilton, ON, Canada connostu@phri.ca.
authors.forename: Stuart J
authors.initials: SJ
authors.lastname: Connolly
authors.forename: Lars
authors.initials: L
authors.lastname: Wallentin
authors.forename: Salim
authors.initials: S
authors.lastname: Yusuf
mesh_terms: D001562:Benzimidazoles / Q000009:adverse effects*; D000069604:Dabigatran; D006470:Hemorrhage / Q000139:chemically induced* / Q000401:mortality; D006801:Humans; D016032:Randomized Controlled Trials as Topic; D020521:Stroke / Q000139:chemically induced; D014859:Warfarin / Q000009:adverse effects*; D015091:beta-Alanine / Q000009:adverse effects / Q000031:analogs & derivatives*
chemical_list: D001562:Benzimidazoles; D015091:beta-Alanine; D014859:Warfarin; D000069604:Dabigatran